Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease ...

Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective ...

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Novartis (NVS) halts the development of ALS drug VHB937 after a Phase 2 trial failure, adding to recent study setbacks. Read ...

Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular ...

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis ...

Novartis AG NVS announced Thursday it terminated a mid-stage trial for an experimental amyotrophic lateral sclerosis (ALS) ...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three ...

Legend Biotech has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth. Zhang officially took the Legend CEO title on Sept. 15, ...

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...